Nalaganje...
Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4
BACKGROUND: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. However, the efficacy of FOLFOX4 for HCC patients is st...
Shranjeno v:
| izdano v: | Asian Pac J Cancer Prev |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
West Asia Organization for Cancer Prevention
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5555527/ https://ncbi.nlm.nih.gov/pubmed/28610406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/APJCP.2017.18.5.1225 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|